Numbers and Facts

The biggest advantage of our company, which offers a new medical technology to the public, may be that we link research and application through our shared vision.

TICEBA - Company - Numbers and facts

 

  • Discovery of the new ABCB5 glycoprotein by Prof. Markus Frank, which marks the pluripotent stem cells in the skin
  • Founding of TICEBA GmbH in the year of 2003 by Dr. Christoph Ganss
  • Start of business activities in March 2005
  • Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells. TICEBA also possesses the license within the meaning of §20b (1 and 2), §20c, and §72b of the AMG for the authorization for the extraction of tissue, the treatment or processing, preservation, testing, storage, import of tissue or tissue preparations
  • Offices and laboratory at technology park Heidelberg
  • More than 50 employees
  • Global business activities
News
Clinical Trials

We are now also recruiting patients for further clinical studies in phase I/IIa with allogeneic ABCB5-positive (ABCB5+) mesenchymal stem cells for the following indications: chronic venous ulcer (CVU), diabetic foot ulcer (DFU) and peripheral arterial occlusive disease (PAOD). For more information click HERE.

License

Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.

Newsletter